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1,2 The sum of rare and common genetic variants robustly identified through linkage and genomewide association studies (GWAS) explains only 1% to 2% of the population variation in BP and hypertension, and the paucity of signals from large-scale GWAS of BP traits indicates that part of the missing heritability is likely to lie in additional undiscovered common or low frequency variants not currently captured in GWAS single nucleotide polymorphism (SNP) arrays. 3, 4 Human and animal data strongly suggest that the locus encompassing the CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone synthase) genes could be involved in common forms of hypertension. The locus is causally implicated in rare but important monogenic syndromes associated with cardiovascular dysfunction: aldosterone synthase deficiency leads to salt wasting and hypotension; 11β-hydroxylase deficiency results in mineralocorticoid hypertension as a result of excess deoxycorticosterone production. A chimeric gene comprising the regulatory region of CYP11B1 and the coding region of CYP11B2 is the cause of glucocorticoid-remediable aldosteronism.
Previous studies investigating the role of CYP11B2 in essential hypertension relied on relatively small and underpowered case/ control studies, with the majority examining a polymorphism in the 5′ regulatory region of CYP11B2 (-344C/T; rs1799998). This variant is in close linkage disequilibrium (LD) with a complex CYP11B2 polymorphism, which replaces a section of so-called wild-type (Wt) sequence within intron 2 with the corresponding region of CYP11B1; this latter form is termed an intron conversion (Conv). There have been reports of rs1799998 and this Intron2 polymorphism associating with hypertension but considerable heterogeneity exists among studies. [5] [6] [7] [8] Here, we identify significant associations between hypertension and polymorphisms at the CYP11B1/CYP11B2 locus in a large, well-phenotyped case/control cohort, followed by confirmation in a separate population. We also identify significantly altered in vivo gene expression that associates with these same polymorphisms, thereby providing a plausible biological explanation for their hypertensive effect.
Methods

Case-Control Cohorts
The first (discovery) cohort comprised 1700 unrelated hypertensive cases and 1700 normotensive controls from the Medical Research Council (MRC) British Genetics of HyperTension (BRIGHT) Study (http://www.brightstudy.ac.uk), of which 1643 cases and 1697 controls were analyzed for this study. 9 The second cohort, of Swedish origin, 10 consisted of a total of 1621 hypertensive individuals from the Nordic Diltiazem study (NORDIL) and 1699 controls from the Malmö Diet and Cancer study (MDC), of which we analyzed 1612 cases and 1317 controls ( Table 1 ). The disparity between total subjects and the analyzed number was because of sample loss, sample failure or, in the case of Swedish controls, of sample removal on the basis of ancestry (see below). Recruitment strategies and ethical permissions for these studies have been described previously. [11] [12] [13] BRIGHT subjects were of white British ancestry by grand-parental origin. All BRIGHT cases had onset of hypertension <60 years with BP ≥150/100 mm Hg (1 reading) or ≥145/95 mm Hg (mean of 3 readings while seated), representing the top 5% of the British distribution. Cases were age-(18-75 years) and sex-matched to controls. BRIGHT controls had BP recordings of ≤140 mm Hg systolic BP and ≤90 mm Hg diastolic BP and were recruited from similar geographic regions to the cases. BRIGHT subjects with body mass index >35 were excluded. Swedish study cases had ≥2 consecutive measurements of ≥160 mm Hg systolic and ≥100 mm Hg diastolic, representing the top 2% of the Swedish population. Swedish controls were ≥50 years of age with systolic BP≤120 mm Hg and diastolic BP≤80 mm Hg and were free from cardiovascular events (coronary events and stroke) during the 10-year follow-up. Cases from both studies were on antihypertensive therapy, but their controls were not. Subjects with any suggestive clinical features of secondary hypertension were excluded from the studies. Imaging studies or measurements of aldosterone/renin ratios to confirm that patients had only primary hypertension were not performed in the cohorts.
Although detailed investigations to exclude, formally, secondary forms of hypertension were not carried out, we believe that the use of these clear ascertainment criteria minimized misclassification within both cohorts. A similar approach has been applied in the majority of other major studies of the genetic basis of hypertension.
Polymorphism Selection and Genotyping
Polymorphisms for genotyping were selected on the basis of previous publications and a HapMap2 CEU screen for tag SNPs in the genomic region (see the online-only Data Supplement for further details). Six polymorphisms (rs6410, rs149845727, rs142570922, rs4546, Intron2, and rs1799998) were genotyped in both studies. Initially, genotypes were identified by direct sequencing, but introduction of specific SNP assays during the course of the project (Applied Biosystems, United Kingdom) enabled genotyping of rs1799998 in the Swedish study, rs6410 in the BRIGHT study, and rs4546 in both studies to be performed using TaqMan technology. To reduce the probability of miscalling, positive and negative quality controls were used throughout and ≈5% of samples from both studies were genotyped in duplicate, yielding consistent results. Finally, rs6410 genotype data for the second study were extracted from genome scan data obtained by Illumina 610 Quad chip array. All genotype assignments were performed blind with regard to clinical data (see the online-only Data Supplement and previous publications). 14, 15 Of the 6 polymorphisms we genotyped for this study, 4 (rs149845727, rs142570922, rs4546, and Intron2) are not represented on any commercial SNP chips; rs6410 is captured on most Illumina (but not Affymetrix) SNP arrays, whereas rs1799998 is represented on newer 1M Illumina SNP and gene-centric IBC chips.
In Vivo Expression Studies
Using a method adapted from Albrecht et al, 16 we compared the relative levels of mRNAs transcribed from the Haplotype1 or Haplotype2 forms of the CYP11B1 or CYP11B2 genes (Figure) in heterozygous adrenal tissue samples ( Figure S3 ). This haplotype-specific expression of the CYP11B1 and CYP11B2 genes was analyzed, in triplicate, in 5 heterozygous adrenal cDNA samples. Briefly, after the requirements of the Human Tissue Act, human adrenal tissue was removed from 11 white adult patients in the course of kidney transplant surgery and verified as nontumorous by histopathologic examination. Genotyping showed 5 of these subjects to be heterozygous for Haplotype1 and Haplotype2; adrenal cDNA was prepared and subjected, in triplicate, to CYP11B1-or CYP11B2-specific polymerase chain reaction, designed to amplify Haplotype1 and Haplotype2 forms of the genes with equal efficiency. Resulting polymerase chain reaction product was cloned into plasmids and used to transform cells, which were grown as colonies on selective media. Plasmid DNA from individual colonies was sequenced and scored as Haplotype1 or Haplotype2 on the basis of silent, exonic polymorphisms (rs6410, rs5283, rs4539, and rs4546) in complete LD with the noncoding polymorphisms. The ratio of Haplotype1:Haplotype2 colonies was a measure of the relative proportions of Haplotype1 and Haplotype2 mRNA in the original tissue sample (see the online-only Data Supplement for further methodological details). 
Statistical Analyses
Using Pearson χ 2 tests, each SNP was assessed to determine whether the observed genotype frequencies in both cohorts were consistent with the expected Hardy-Weinberg proportions (see Table S3 in the onlineonly Data Supplement). Single-marker analyses were performed using logistic regression under an additive model as implemented in PLINK. 17 For Swedish samples, previous GWAS gave us access to principal components allowing adjustment for population stratification. 12 Five principal components were included as covariates in the logistic regression. LD between each pair of SNPs was evaluated using Lewontin D′, as well as R 2 (see Figure S2 ). We performed haplotype analyses of SNPs in LD in CYP11B1 and CYP11B2. Associations between haplotypes and hypertension were evaluated by scoring the haplotypes using generalized linear models implemented in haplo.stats, and empirical P values were obtained from the score statistics using permutation (http:// mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm).
Combined analysis of the single-marker and haplotype association tests were performed by combining study-specific regression β coefficients using the inverse variance fixed-effect method. 18 The Bonferroni-corrected P value for 6 independent tag SNPs of 0.0083 was used as the threshold for significance in this study. For haplotype analysis, empirical P values were generated through permutation.
The ascertainment criteria for hypertension in both cohorts were as described above, with age and BMI thresholds used for BRIGHT and age thresholds only for the Swedish. For this reason, the distribution of BP and other phenotypes was found to differ between populations, and subsequent phenotypic adjustment in our analyses was not deemed appropriate.
Results
Demographic details of both cohorts are presented in Table 1 . In both, there was high LD across the CYP11B1 and CYP11B2 locus with the Lewontin D′>0.80 and R 2 >80. LD plots are shown for both cohorts in Figure S2 .
Single-Marker Analysis
Results of single-marker association analysis for the 6 genotyped polymorphisms are shown in ).
Haplotype Analysis
The haplotype results across the CYP11B1 or CYP11B2 genes are shown in Table 3 . The most common haplotypes for CYP11B1 (GTC, frequency 51%) and CYP11B2 (CConvT, frequency 44%) were used as reference haplotypes. For CYP11B1, the common haplotype ACA (frequency 44%) showed association for hypertension (combined analysis OR, 1.11; 95% CI, 1.03-1.20; P=7.4×10 and P=1.6×10 −14 , respectively). For CYP11B2, 2 common haplotypes, TWtC and CWtT (frequencies 41% and 11%, respectively), showed similar association with lower risk of hypertension relative to CConvT (combined analysis OR, 0.88; 95% CI, 0.81-0.96; P=2.2×10 −3 and OR, 0.8; 95% CI, 0.7-0.91; P=5×10 −4 , respectively). In contrast to the common haplotypes, which appeared with similar frequency in both study groups, less common haplotypes showed greater variability between groups in terms of frequency and consistency of effect (eg, TConvC). (Table 4) showed that individual gene haplotypes with the same directionality of risk for hypertension tend to coexist. Haplotypes containing the Wt Intron2 allele associated with lower risk of hypertension compared with the reference haplotype ACACConvT. One such haplotype, GTCTWtC, has a frequency of ≈38% and associates with a combined OR of 0.89 in the combined analysis (95% CI, 0.82-0.97; P=6.9×10 −3 ). Again, whereas the frequencies of common haplotypes were consistent between BRIGHT and Swedish cohorts, those of the less frequent haplotypes differed between populations.
In Vivo Expression Studies
We defined the common haplotype ACACConvT (comprising rs6410, rs149845727, rs142570922, rs4546, Intron2, and rs1799998; Figure A) formed across CYP11B1/B2 as Haplotype1 and the contrasting GTCTWtC as Haplotype2 and analyzed the haplotype-specific transcription of each gene separately. For CYP11B1, colonies derived from Haplotype2 were consistently and significantly more abundant than those from Haplotype1, the latter representing 41% of total positive colonies (P<0.003; 95% CI, 37% and 45%; Figure B ). For CYP11B2, the numbers of Haplotype1 and Haplotype2 colonies were again unequal but here Haplotype1-derived colonies were consistently in the majority, except for one outlying result for Sample 2, which we attribute to sampling error ( Figure B ). Haplotype1-derived colonies represented 60% of total positive colonies (P<0.02; 95% CI, 53% and 66%).
Discussion
Our combined analysis and complementary functional data support a role for both CYP11B1 and CYP11B2 in the development of hypertension, with evidence for 2 distinct regions Where no data are shown, subjects of that haplotype were not detected within the cohort. OR indicates odds ratio; Wt, wild-type; Conv, conversion; P, P value for the haplotype in the association test; and Q, P value for heterogeneity.
by guest on August 30, 2017
http://hyper.ahajournals.org/ Downloaded from across this locus that contribute to the risk of hypertension, one encompassing intron 2 of CYP11B2, the other the 5′ regulatory region of CYP11B1. This digenic pattern is reminiscent of the mutations in both genes in the Dahl rat, which are implicated in its development of salt-sensitive hypertension. [19] [20] [21] We believe our data are the first to demonstrate a hypertensive role for a locus that is already implicated in rare monogenic disorders affecting BP and in a rodent model. Furthermore, this is the first study in 2 large white populations in which an association of hypertension with Intron2 Conv polymorphism has been confirmed. Previously, only a few small studies have reported similar findings, perhaps reflecting the complexity of Intron2 Conv genotyping. 7, 8 In contrast, genotyping of the -344C/T (rs1799998) has been performed in several cohorts with different ethnicities. Sookoian et al 5 performed a meta-analysis of 19 studies and 11 225 individuals and reported association between hypertension and subjects homozygous for rs1799998 T. Recently, Takeuchi et al 6 reported similar findings in a replication study and meta-analysis of Japanese subjects, where rs1799998 had a significant association with systolic BP, diastolic BP, and hypertension. 6 Our study populations, each more than twice the size of the largest used by Sookoian et al, 5 allowed us to perform combined analysis using an additive model, in contrast to the dominant model they used. We therefore repeated our analysis in this way (dominant model), adding all individuals from the Sookoian meta-analysis to produce a combined meta-analysis of 17 470 individuals. This showed significant heterogeneity (I 2 =61.1% [42.6%;73.7%]; Q-test for heterogeneity=77.18, P<0.001) and no evidence of association between rs1799998 T and hypertension. It is important to note that our single SNP analysis showing a suggestive protective effect of the C allele is in agreement with the findings of Sookoian et al. 5 This is reinforced by our population analysis, where haplotypes containing the C allele tended to be protective, and by our in vitro analysis, which found the C allele to associate with reduced CYP11B2 transcription. We suggest that ethnic differences are the most likely reason we did not identify the association between rs1799998 and hypertension reported by Sookoian et al 5 and Takeuchi et al. 6 The BRIGHT recruitment policy (ie, subjects of white ancestry by grand-parental origin, with similar geographic location) and adjustment for population stratification in the Swedish study were designed to reduce ethnic admixture in our cohorts. Cases were on treatment but, because our analysis treated hypertension as a qualitative trait, correction for the effects of antihypertensive therapy was not required. Although we did not actively screen subjects for secondary forms of hypertension, our recruitment policy excluded subjects with any feature suggestive of a secondary cause. Our inclusion of subjects with a positive family history and onset at <60 years of age maximized the likelihood of including subjects with primary hypertension. Such approaches have been consistently followed in numerous other studies of the genetic basis of hypertension. We conclude that the most important signal in CYP11B2 is associated with the variation represented by the intron 2 conversion, which has been analyzed in very few previous studies, or by a variant in close LD with rs1799998. We found no consistent association between single CYP11B1 SNPs and hypertension in the populations, but analysis of the common ACA CYP11B1 haplotype showed weakly positive association with hypertension in combined cohort analysis. Two low-frequency CYP11B1 haplotypes incorporating SNPs from the 5′ regulatory region of the gene showed much stronger association, although the CIs spanning these estimates were wide (Table 3) . While the importance of these low-frequency haplotypes to population risk of hypertension is unclear, it has been suggested that risk of high BP is more likely to be the cumulative result of highly influential but individually lowfrequency variants. 22 Indeed, simulation studies by Dickson et al 23 show that signals detected for common variants could, in principle, result from the effect of low-frequency variants; this raises the possibility that the signal from the common Intron2 Conv variation derives from underlying low-frequency, largeeffect variants. Certain less frequent (ie, <0.02) haplotypes were present in 1 but not both populations; we believe this is a result of ethnic differences between the 2 cohorts, which result in slightly different LD patterns and consequent differences in the frequencies of these haplotypes.
CYP11B2 haplotypes containing the Intron2 Wt variant are protective against high BP, with similar directionality of effect in both cohorts. Of the 2 common haplotypes spanning the whole CYP11B1/CYP11B2 region, the one containing Intron2 Wt again had a consistently protective effect in both cohorts. To capture the causal variations throughout the CYP11B1/ CYP11B2 region with greater precision, we attempted imputation of SNPs from online databases, but much of this information did not correlate with our own genotyping data from the cohorts; in particular, discrepancies arose around the CYP11B2 Intron2 polymorphism, where homology between CYP11B1 and CYP11B2 is particularly high, especially in the Conv form. We believe that the genetic architecture of this region makes sequence alignment of the type used by large study databases subject to error. This limits the utility of imputed genotypes, and we advise caution when interpreting data from this locus that are not based on validated, directly genotyped results of the type used here. GWAS studies are blind to low-frequency variants and most have focused on single-marker analysis. Our study highlights this potential gap in current common variant analysis which, although partly addressed by gene-centric chips like the CVD50 and metabochip, still requires the locus of interest to be selected, usually on the basis of GWAS experiments. This study also demonstrates that regions exhibiting high sequence similarity are less amenable to high-throughput technologies.
Our investigation of these polymorphisms' functional impact on CYP11B1 and CYP11B2 gene transcription in vivo used sequential RT-polymerase chain reaction, cloning, and sequencing to determine what proportion of each gene's total mRNA derived from Haplotype1 or Haplotype2 within heterozygous adrenal tissue samples. The advantages of this approach were several. First, direct quantitative measurement of each mRNA by Taqman-based RT-polymerase chain reaction was simply not possible because of the high degree of sequence similarity between the 2 genes and their almost identical allele-specific forms. Second, our method removed the need to correct for variable levels of CYP11B2-expressing zona glomerulosa and CYP11B1-expressing zona fasciculata within different tissue samples, because the variant forms of each gene were only being compared against one another. Finally, because our method measures relative rather than absolute levels of each gene's 2 variant forms, it also removes the need to correct or allow for the natural physiological variation in total CYP11B1 or CYP11B2 transcripts that will inevitably occur between individual tissue samples. The haplotypes of the study tissue samples were inferred by direct genotyping of genomic DNA at the key polymorphic sites. The haplotype source of mRNAs was determined on the basis of transcribed SNPs within the coding region known to be in LD with the untranscribed or intronic polymorphisms obviously absent from the mRNA sequence. Having carefully verified this method (Figure S4) , we showed the Haplotype2 form of CYP11B2 mRNA, associated here with nominally reduced risk of hypertension, to be underrepresented (ie, to comprise <50% of total CYP11B2 transcripts); the Haplotype2 form of CYP11B1 mRNA was, however, overrepresented (>50% of total CYP11B1 transcripts) in heterozygous samples. These are subtle but significant differences in mRNA levels, which provide a simple putative mechanism to explain the association, reported elsewhere, of Haplotype2 polymorphisms with lower aldosterone levels 7, 24 and greater 11β-hydroxylation efficiency. 25, 26 These findings are also consistent with the known association between SNPs in the 5′ regulatory region of CYP11B1 and minor impairment of 11β-hydroxylation efficiency 14 ; the relevance of this to the long-term risk of hypertension has been the subject of a detailed review elsewhere. 27 We do not have data on circulating corticosteroid levels in the cohorts studied, and the links among genotype, intermediate biochemical phenotype, and BP still need to be clarified. Finally, the mechanism by which Intron2 affects gene expression remains unidentified, but it remains possible that it is a marker for another linked functional polymorphism; further studies of this complex region are warranted.
Perspectives
There is extensive evidence that the CYP11B2 (aldosterone synthase) and CYP11B1 (11β-hydroxylase) genes are involved in the development of hypertension; few loci have such a compelling biological link between genotype and phenotype, and our data provide important functional support for this. In turn, they raise important questions about the importance of aldosterone in cardiovascular disease. The major CYP11B1/ CYP11B2 haplotypes associate with altered adrenal expression of both genes and with the population risk of hypertension, occurring with a frequency that has major implications for the treatment of cardiovascular disease. These, along with evidence from the Framingham population and our own studies examining aldosterone's relationship with hypertension, highlight its importance in long-term population cardiovascular risk, an effect likely to be amplified by prevailing sodium intake. These novel data underline the importance of the CYP11B1/CYP11B2 locus in hypertension and bring to the fore therapeutic efforts to target mineralocorticoid synthesis and action.
What Is New?
• These 2 large population studies in whites show association of the Intron2
Conv allele in the CYP11B2 gene with higher risk of essential hypertension. In addition, a common haplotype spanning the CYP11B1 and CYP11B2 genes correlates with higher risk of hypertension and also corresponds to in vitro results showing increased CYP11B2 expression and decreased CYP11B1 expression.
What Is Relevant?
• These results confirm the significant contribution of common genetic polymorphisms at the CYP11B1/CYP11B2 locus to essential hypertension and suggest a functional basis for this association.
Supplemental Methods
Rationale for polymorphism selection in the CYP11B1/CYP11B2 locus SNPs in the CYP11B1/CYP11B2 locus were selected for inclusion in this study either because they had been reported as functional in previous studies (e.g. rs1799998), or because they were identified as tagSNPs in our pilot study. This pilot study was designed to dissect in detail the polymorphic variations of this locus in Caucasian subjects. We analysed 79 Caucasian unrelated offspring (50 hypertensives and 29 normotensives) from the BRIGHT transmission disequilibrium test (TDT). Our aim was to estimate linkage disequilibrium (LD), haplotype structure and haplotype tagSNPs (htSNPs) for the CYP11B locus. As SNPs are abundant in this locus and high-throughput genotyping was available, in order to allow fine mapping of a causal variant, it was decided that a combination of a selection of potential causal variants (-344, -1889 and -1859) and a set of several markers (htSNPs) capturing most of the information in the region would be appropriate. The most informative regions across the CYP11B1/CYP11B2 locus were identified by reviewing LD plots using the HapMap CEU (HapMap Release #20 and #22). However, sequencing of this region is difficult because of the similarity between these genes and, therefore, the HapMap coverage of this region was incomplete. Barr et al. previously sequenced the CYP11B1 and CYP11B2 genes extensively in 26 normotensives subjects from the MONItoring of trends and determinants in CArdiovascular disease (MONICA) IV study (Barr et al. 2007 ). The HapMap data for Caucasians combined with the 26 normotensive subjects from the MONICA study were used to select a set of SNPs that would capture the variability in the region (see Figure S1 ). In order to have 90% coverage of this locus, 15 SNPs in the CYP11B1/CYP11B2 were selected for genotyping (see Table S1 ). Four individuals were excluded because their genotype call rate was <50%. As there is significant LD in the locus and there is currently no consensus for selecting haplotype blocks or their boundaries, two blocks were chosen to ensure the best selection of htSNPs: Block 1 comprised SNPs in the CYP11B1 plus the intergenic region and Block 2 comprised SNPs in the CYP11B2 plus the intergenic region. For Block 1, by using rs5301 in the 3'UTR region, rs6410 in exon 1 and rs142570922 in the CYP11B1 promoter, 100% of alleles were captured with r 2 >0.8. For Block 2, rs4736354 in the intergenic region, rs4546 in exon 3, the Intron2 polymorphism and rs1799998 in the promoter of the CYP11B2 gene were used. Therefore, these two blocks predicted 90% coverage of the most common haplotypes and the remaining SNPs. In addition to these criteria, the performance and cost of the genotyping assays, the interruption of LD over short distances with the presence of a conversion and the strength of association in the discovery (BRIGHT) cohort were also considered, leading to a final selection of six htSNPs in the two cohorts (see Table S3 ).
Genotyping
PCR of genomic DNA for Direct Sequencing
For the discovery stages of this study, the rs1799998 SNP was genotyped by direct sequencing. A 232bp fragment encompassing the rs1799998 SNP was amplified using 25ng template DNA in a 25µl reaction volume and 1.25U Thermo-Start DNA Polymerase (ABGene, Surrey UK), according to manufacturer's protocol. Oligonucleotide primers SF1F and SF1R (Table S2) were added at a final concentration of 10µM. The reactions were subjected to the following PCR conditions: a single cycle at 94°C for 15min, followed by 30 cycles at 94°C for 30s, 68°C for 30s, 72°C for 1min and then incubated at 72°C for 7min.
A 600bp fragment in intron 2 of CYP11B2, encompassing the Intron2 polymorphism, was amplified using 50ng template DNA in a 25µl reaction volume and 0.625U Thermo-Start DNA Polymerase (ABGene, Surrey UK), according to manufacturer's protocol. Oligonucleotide primers ICTAQMANF and ICTAQMANR were added at a final concentration of 20µM. The reactions were subjected to the following PCR conditions: a single cycle at 95°C for 15min, followed by 45 cycles at 95°C for 15s, 62°C for 30s, 72°C for 2min and then incubated at 72°C for 7min.
A CYP11B1 promoter fragment including rs142570922 and rs149845727 was amplified using a nested PCR to achieve specificity, as optimised by Barr et al. In the first step, the same amount of template, reaction volume and 1.25U Thermo-Start DNA Polymerase as for rs1799998 was used. Oligonucleotide primers (concentration 10µM) B1 5'UTR and B1Prom260 were added. The cycling conditions were: 95°C for 15 minutes followed by 35 cycles of 95°C for 30s, 60°C for 30s and 72°C for 3 minutes, finishing at 72°C for 7 minutes. Then the PCR products were diluted 1:10 in nuclease free water, using 1µL PCR product as a template. 1µL diluted template DNA was amplified in a 25µl reaction volume using 0.625 U Thermo-Start DNA Polymerase (ABGene, Surrey UK). Oligonucleotide primers B1 5'7-32 and B1 369-393 at 10µM were added. The amplification conditions were 95°C for 15 minutes followed by 20 cycles of 95°C for 15s, 60°C for 30s and 72°C for 1 minutes, finishing at 72°C for 7 minutes; a PCR product of 387bp was obtained.
Sequencing reactions
All PCR products were cleaned for sequencing using AMPure (Agencourt, USA) according to the manufacturer's protocol. 10µL of cleaned PCR product was used for sequencing by the BigDye Terminator v3.1 kit (Applied Biosystems, USA) according to the manufacturer's protocol, along with the corresponding sequencing primers. The rs1799998 products were sequenced with SF1F at a concentration of 3.2µM and cycled at 45s at 96°C, 25s at 50°C, 4min 60°C for 25 cycles. The CYP11B2 Intron2 products were sequenced with primer INTCONR(B1B2) and the CYP11B1 promoter products with primer B1PROM 250-229AS, both at 3.2µM concentration, cycled for 45s at 96°C and 4min at 60°C for 25 cycles.
Sequencing products were cleaned using CleanSEQ (Agencourt, USA) according to the manufacturer's protocol. DNA sequences were analysed using a 3730 DNA Analyzer (ABI, USA) and visualized using SeqScape version 2.1.1. Samples were excluded when the chromatogram was judged of poor quality following two attempts at genotyping. See Table S1 for primer sequences.
Validation of TaqMan® assay for SNP rs1799998
The TaqMan® assay (Applied Biosystems, UK) for rs1799998 was made available after the discovery phase had been completed and was adopted for the second (Swedish) study. To confirm that the results for this assay were consistent with those obtained by direct sequencing, 90 BRIGHT samples were re-genotyped by Taqman. All genotyping calls obtained by Taqman assay matched those obtained by direct sequencing (data not shown).
In vivo Expression Studies
Preparation of human adrenal cDNA Total RNA was isolated from frozen adrenal tissue using the RNeasy® Lipid Tissue Mini kit (QIAGEN, Crawley, U.K.), according to the standard protocol, the resulting RNA being DNased using the Turbo DNA-free kit (Applied Biosystems) and quantified using the NanoDrop spectrophotometer. Genomic DNA was isolated from frozen tissue using the DNeasy Blood & Tissue kit (QIAGEN) according to the standard protocol. Samples were genotyped for key polymorphisms at the CYP11B1 and CYP11B2 by a combination of direct sequencing and Taqman assays. On the basis of these results, 5 tissue samples were found to be heterozygous for Haplotypes 1 and 2, as defined in Figure 1A . Total adrenal RNA from these samples was reverse transcribed using the ImPromII Reverse Transcription System (Promega, Southampton, U.K.), according to the standard protocol, using 2mM MgCl 2 , 0.5µg random primers and 0.5µg total RNA template. Negative control reactions omitting reverse transcriptase were also performed.
Measurement of relative levels of Haplotype1-and Haplotype2-derived
CYP11B1 and CYP11B2 cDNA A summary of this method is provided in Figure S3 . Briefly, 2µL human adrenal cDNA was subjected to PCR of either CYP11B1 or CYP11B2 using FastStart Taq (Roche, Mannheim, Germany) according to the standard protocol. PCR of CYP11B1 cDNA used primers B1ASPCRF and B1ASPCRR, while CYP11B2 amplification used primers B2ASPCRF and B2ASPCRR (See Table S1 ). Resulting PCR product was cloned into the pCR®4-TOPO® plasmid vector, which was then used to transform One Shot® TOP10 Competent Cells, according to the standard chemical transformation protocol of the TOPO TA Cloning Kit for Sequencing (Invitrogen, Paisley, U.K.). These cells were spread on warmed LB agar plates containing 50µg/mL kanamycin and incubated overnight at 37°C. The next day, 96 colonies resulting from each transformation were picked randomly and suspended in water. Colony plasmid DNA was amplified using the PlasmidAmp kit (QIAGEN, Crawley, U.K.) according to the standard protocol, then sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit and the M13F primer. Sequences resulting from CYP11B1 amplification were classified as belonging to either Haplotype1 or Haplotype2 categories on the basis of the rs6410 SNP, while positive CYP11B2 sequences were classified on the basis of the rs4546 SNP ( Figure 1A ).
Negative samples either contained no readable sequence or contained sequence corresponding to genomic DNA, presumably as a result of incomplete DNasing of the original adrenal RNA sample. The resulting numbers of positive Haplotype1 and Haplotype2 colonies were subjected to a one sample t-test.
Method validation
To ensure there was no inherent bias in the above method, validating experiments were performed using plasmids in place of adrenal cDNA. These plasmids, a gift from Professor Perrin White, contained CYP11B1 or CYP11B2 cDNA in a pGL3 backbone; as supplied, the plasmids were found to correspond to CYP11B1 Haplotype1 and to CYP11B2 Haplotype2, so were named pB1Hap1 and pB2Hap2, respectively. The opposite forms, pB1Hap2 and pB2Hap1, were generated using the original plasmids, the QuikChange® Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), and specific SDM primers (Table S1 ). Resulting plasmids were purified using the QIAfilter Plasmid Midi kit (QIAGEN, Crawley, U.K.) and sequence was confirmed using the BigDye Terminator v3.1 Cycle Sequencing Kit and the M13F primer, as above. Using these plasmids as template, we found that the RT-PCR primers designed for the separate amplification of the highly-homologous CYP11B1 or CYP11B2 cDNAs were specific. Furthermore, by mixing together varying amounts of pB1Hap1 and pB1Hap2, or of pB2Hap1 and pB2Hap2, then subjecting this template DNA to the appropriate protocol, as above, we could demonstrate that the resulting numbers of Hap1-and Hap2-containing cell colonies was not preferentially biased towards one particular form (see Figure  S4 ). In vivo Expression GCA GCA CCT TCT TCT TCA GGG CCT GGG AGA AGT CCC TGG CCA C
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